LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported U.S. net product revenues of $120.1 million (unaudited) for the fourth quarter of 2008 for its antibiotic product CUBICIN® (daptomycin for injection). This result represents an increase of 43%, or $36.2 million, from fourth quarter 2007 U.S. CUBICIN net product revenues. Full year 2008 U.S. CUBICIN net product revenues were $414.7 million (unaudited). This result represents an increase of 45%, or $129.6 million, from full year 2007 U.S. CUBICIN net product revenues. Cubist’s share of full year 2008 international net product revenues was $7.4 million (unaudited). This represents an increase of $2.1 million from full year 2007. Included in the full year 2008 total net revenues is $9.4 million of service revenue (unaudited) relating to Cubist’s exclusive agreement with AstraZeneca to sell and provide other support in the United States for MERREM® I.V. (meropenem for injection).
